Zhongliu Fangzhi Yanjiu (Apr 2024)

Progress of Targeted Therapy and Immunotherapy for Gastric Cancer

  • ZHENG Yu,
  • PAN Hongming

DOI
https://doi.org/10.3971/j.issn.1000-8578.2024.23.1257
Journal volume & issue
Vol. 51, no. 4
pp. 234 – 239

Abstract

Read online

Gastric cancer (GC) is a common malignant tumor of the digestive tract in China. It is characterized by high morbidity, mortality, and proportion of patients in advanced stages. In the past years, chemotherapy was used as the main treatment for GC. Subsequently, targeted therapy with trastuzumab was approved to treat HER2-positive GC. However, the progress of drug development and clinical studies has been limited by the high heterogeneity of GC. In recent years, research on immunotherapy and new targets for therapeutic exploration in GC has made great strides. Herein, we provide a brief review of the progress of the research on targeted therapy and immunotherapy for GC.

Keywords